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1. INTRODUCTION {#jcmm13672-sec-0001}
===============

Systemic lupus erythematosus (SLE) is a chronic autoimmune disorder disease characterized by breakdown of tolerance to self‐antigens and production of multiple autoantibodies and immune complexes.[1](#jcmm13672-bib-0001){ref-type="ref"} SLE has higher morbidity, disability and mortality rates. Thus, both the quality of life and life expectancy in patients are seriously influenced. In China, the prevalence rate of SLE is about 0.03%: higher than in Japan, or Europe and America.[2](#jcmm13672-bib-0002){ref-type="ref"} The aetiology of SLE has not been fully elucidated clearly. Recent studies showed that genetic factors might be associated with the individual susceptibility to SLE. Previous studies have been established that genes have important effects on the development of SLE such as *LEP* and *LEPR* gene, *Fc*γ*R* gene, miRNA‐146a.[3](#jcmm13672-bib-0003){ref-type="ref"}, [4](#jcmm13672-bib-0004){ref-type="ref"}, [5](#jcmm13672-bib-0005){ref-type="ref"} Successes from these studies generally explain only part of disease heritability in SLE. Hence, the molecular genetic basis of this disease remained deficiently understood.

MiR‐17‐92 displays different expression level during B‐cell development: they are enhanced level in progenitor cells, and their expression decreases highly when pre‐B becomes immature B cells.[6](#jcmm13672-bib-0006){ref-type="ref"} MiR‐17‐92 expression is up‐regulated in CD4^+^ T cells from lupus patients and multiple sclerosis.[7](#jcmm13672-bib-0007){ref-type="ref"}, [8](#jcmm13672-bib-0008){ref-type="ref"} Decreased expression of miR‐17‐92 has been found during differentiation towards CD8^+^ T cells.[9](#jcmm13672-bib-0009){ref-type="ref"} It is generally recognized that these immune‐related cells were related to the development of SLE.

To date, no report was carried out to investigate the association of SNPs in *miR‐17‐92* and SLE risk, and the relationship between *miR‐17‐92* gene SNPs and the expression of plasma miR‐17‐92 family members in SLE patients. We use EPD (<http://www.epd.isb-sib.ch/>) and miRbase (<http://www.mirbase.org/>) to predictive promoter. Then, the SNPs of Minor allele frequency (MAF) greater than 10% were selected by UCSC (<http://genome.ucsc.edu>) in the Chinese population. Therefore, we evaluate the association of the three SNPs (rs9515692 and rs1352743) in the promoter region of *miR‐17‐92* with susceptibility to SLE and further investigate the influence of *miR‐17‐92* polymorphisms on critical plasma levels and various disease clinical features.

2. MATERIALS AND METHODS {#jcmm13672-sec-0002}
========================

2.1. Subjects of study {#jcmm13672-sec-0003}
----------------------

The study comprised 312 patients (62 males and 250 females) with SLE diagnosed according to the American College of Rheumatology classification (ACR) 1997 criteria for SLE. At the same time, 396 ethnically matched healthy controls (98 males and 298 females) without any history of autoimmune disease, inflammatory and chronic infectious diseases were selected. The clinical characteristics of patients and controls are shown in Table [S1](#jcmm13672-sup-0001){ref-type="supplementary-material"}. The patients and healthy individuals were selected at the Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, China. The Ethics Committees of Affiliated Hospital of Youjiang Medical University for Nationalities approved this study protocol. The study was carried out in accordance with the relevant guidelines. Written informed consent was obtained from all the participants.

2.2. DNA extraction and miR‐17‐92 genotyping {#jcmm13672-sec-0004}
--------------------------------------------

EPD (<http://epd.vital-it.ch/index.php>) and miRbase (<http://www.mirbase.org/>) were used to predictive promoter. We conducted a search for the *miR‐17‐92* gene single nucleotide polymorphisms (SNPs) with a minor allele frequency (MAF) ≥ 10% and label SNPs within the Han Chinese population (CHB) of Beijing, China. Genomic DNA was extracted using whole‐blood genome DNA extraction kit (Tiangen Inc., Beijing, China). The designs of PCR primers were carried out by online primer 3.0 software (<http://primer3.ut.ee/>). SNaPshot was used to analyse genotypes of SNPs. The PCR primers are shown in Table [S2](#jcmm13672-sup-0001){ref-type="supplementary-material"}.

2.3. Quantitative PCR of miR‐17‐92 {#jcmm13672-sec-0005}
----------------------------------

Total RNA was isolated from 100 μL plasma performed with a commercial kit (Takara, Dalian, China) following the manufacturer\'s protocol. Five microgram of total RNA was transcribed into cDNA utilizing Mir‐X miRNA First‐Strand Synthesis Kit (Takara, Cat. No. 638315). Quantitative PCR was performed using Mir‐X miRNA qRT‐PCR SYBR Kit (Takara, Cat. No.638313) and ABI 7900HT real‐time PCR machine (Applied Biosystems, CA, USA). The 3^′^ primers for quantitative PCR are mRQ 3^′^ Primer supplied with the kit. Cel‐miR‐39 was used as an internal control. Relative expression levels of miR‐17‐92 were calculated using the delta‐delta Ct method (2^−ΔΔCt^).

2.4. Statistical analysis {#jcmm13672-sec-0006}
-------------------------

If the data were normally distributed variables, the Student\'s t‐test was used; otherwise, Mann‐Whitney U test was used. Hardy‐Weinberg equilibrium (HWE) was tested using chi‐squared test. Haplotype analysis was performed using SHEsis software (<http://analysis.bio-x.cn/myAnalysis.php>) . OR and 95% CI were adjusted based on age and gender using logistic regression. *P* \< .05 was considered statistically significant.

3. RESULTS {#jcmm13672-sec-0007}
==========

There was no significant difference between cases and controls in age (*P* = .087) and gender (*P* = .124). The distributions of the four SNPs polymorphisms in SLE and controls are shown in Table [1](#jcmm13672-tbl-0001){ref-type="table"}. All genotype distributions were in agreement with the Hardy‐Weinberg equilibrium of any SNP (*P* \> .05). To note, the CT genotype and dominant model (CT+TT) in rs9515692 were associated with decreased risk of SLE (CT vs CC: AOR = 0.65, 95% CI, 0.46‐0.92, A*P* = .014; CT+TT vs CC: AOR = 0.64, 95% CI, 0.46‐0.90, A*P* = .009). In addition, T allele was associated with decreased risk of SLE (T vs C: AOR = 0.69, 95% CI, 0.52‐0.92, A*P* = .010). Nevertheless, no significant association between the remainder two SNPs and SLE was observed (A*P* \> .05).

###### 

Genotype and allele distributions of three SNPs in *miR‐17‐92* in SLE and control groups

  Polymorphisms     SLE (%)      Controls (%)   OR (95% CI)        AOR (95% CI)[a](#jcmm13672-note-0002){ref-type="fn"}   *P*    *AP* [a](#jcmm13672-note-0002){ref-type="fn"}
  ----------------- ------------ -------------- ------------------ ------------------------------------------------------ ------ -----------------------------------------------
  rs9515692                                                                                                                      
  CC                234 (75.0)   260 (65.7)     1.00 (Ref)                                                                       
  CT                68 (21.8)    118 (29.8)     0.64 (0.45‐0.91)   0.65 (0.46‐0.92)                                       .006   .014
  TT                10 (3.2)     18 (4.5)       0.62 (0.28‐1.36)   0.62 (0.28‐1.37)                                       .229   .235
  Dominant model    78 (25.0)    136 (34.3)     0.64 (0.46‐0.89)   0.64 (0.46‐0.90)                                       .007   .009
  Recessive model   302 (96.8)   378 (95.5)     1.44 (0.65‐3.16)   1.44 (0.65‐3.18)                                       .364   .364
  C                 536 (85.9)   638 (80.6)     1.00 (Ref)                                                                       
  T                 88 (14.1)    154 (52.4)     0.68 (0.51‐0.91)   0.69 (0.52‐0.92)                                       .008   .010
  rs1352743                                                                                                                      
  AA                41 (13.1)    51 (12.9)      1.00 (Ref)                                                                       
  AG                164 (52.6)   193 (48.7)     1.06 (0.67‐1.68)   1.08 (0.68‐1.71)                                       .814   .756
  GG                107 (34.3)   152 (38.4)     0.88 (0.54‐1.42)   0.88 (0.55‐1.43)                                       .587   .609
  Dominant model    171 (86.9)   345 (87.1)     0.98 (0.63‐1.52)   0.99 (0.64‐1.54)                                       .918   .964
  Recessive model   205 (65.7)   244 (61.6)     1.20 (0.88‐1.63)   1.20 (0.88‐1.64)                                       .262   .245
  A                 246 (39.4)   295 (37.2)     1.00 (Ref)                                                                       
  G                 378 (60.6)   497 (62.8)     0.91 (0.74‐1.13)   0.91 (0.73‐1.13)                                       .912   .402
  rs1813389                                                                                                                      
  AA                124 (39.7)   164 (41.4)     1.00 (Ref)                                                                       
  AG                157 (50.4)   194 (49.0)     1.07 (0.78‐1.46)   1.08 (0.79‐1.49)                                       .671   .615
  GG                31 (9.9)     38 (9.6)       1.08 (0.64‐1.83)   1.07 (0.63‐1.81)                                       .778   .817
  Dominant model    188 (60.3)   232 (58.6)     1.07 (0.79‐1.45)   1.08 (0.80‐1.47)                                       .653   .615
  Recessive model   281 (90.1)   358 (90.4)     0.96 (0.58‐1.59)   0.98 (0.59‐1.62)                                       .880   .943
  A                 405 (64.9)   522 (65.9)     1.00 (Ref)                                                                       
  G                 219 (35.1)   270 (34.1)     1.05 (0.84‐1.30)   1.05 (0.84‐1.31)                                       .693   .690

Adjusted by age and gender.

miRNA, microRNA; SLE, systemic lupus erythematosus; 95% CI, 95% confidence interval; AOR, adjusted OR value; A*P*, adjusted *P* value; Ref, reference.

John Wiley & Sons, Ltd

Haplotype analysis was performed by online SHEsis software and the three haplotypes (C‐G‐G, C‐A‐A) were associated with increased risk of SLE (OR = 4.46, 95% CI, 2.17‐9.17, *P* \< .001; OR = 2.33, 95% CI, 1.44‐3.76, *P* \< .001, respectively).

Additionally, the expression of miR‐17 in SLE patients was decreased significantly compared with control subject (*P* \< .001; Figure [1](#jcmm13672-fig-0001){ref-type="fig"}A). After confirming the genetic association of rs9515692 with SLE susceptibility, we aimed to analyse if this SNP would have an effect on expression levels on miR‐17‐92. We found that the rs9515692 CT/TT had a higher level of miR‐17 compared with those carrying the rs9515692 CC (*P* = .017; Figure [1](#jcmm13672-fig-0001){ref-type="fig"}B).

![Relative expression of miR‐17 in SLE patients (n = 96) and healthy controls (n = 96). A, Decreased level of miR‐17 in SLE patients compared with healthy controls (*P* \< .001). B, Increased level of miR‐17 in SLE patients carrying the rs9515692 CT+TT compared with those carrying the rs9515692CC (*P* = .017). Data are presented as mean ± standard error. Expression levels were normalized to cel‐miR‐39](JCMM-22-4016-g001){#jcmm13672-fig-0001}

We compared the distribution of genotypic frequencies of rs9515692 between positive and negative patients in thirteen specific clinical manifestations and found that rs9515692 CT+TT and T allele with anti‐dsDNA in distribution of allele and genotype frequencies (CT+TT vs CC: AOR = 0.42, 95% CI = 0.24‐0.72, A*P* = .002; T vs A: AOR = 0.49, 95% CI = 0.31‐0.79, A*P* = .003) (Table [2](#jcmm13672-tbl-0002){ref-type="table"}).

###### 

Association of allele and genotype frequencies in rs9515692 with clinical features in SLE

  Clinical features      Allele \[n\]   AOR[a](#jcmm13672-note-0004){ref-type="fn"}   *AP* [a](#jcmm13672-note-0004){ref-type="fn"}   Genotype \[n\]   AOR[a](#jcmm13672-note-0004){ref-type="fn"}   *AP* [a](#jcmm13672-note-0004){ref-type="fn"}                      
  ---------------------- -------------- --------------------------------------------- ----------------------------------------------- ---------------- --------------------------------------------- ----------------------------------------------- ------------------ ------
  Malar rash                                                                                                                                                                                                                                                            
  Positive               161            27                                            1.05 (0.64‐1.71)                                .850             69                                            25                                              1.16 (0.67‐2.03)   .595
  Negative               375            61                                                                                                             165                                           53                                                                 
  Photosensitivity                                                                                                                                                                                                                                                      
  Positive               302            48                                            0.92 (0.58‐1.45)                                .717             132                                           43                                              0.94 (0.56‐1.58)   .814
  Negative               234            40                                                                                                             102                                           35                                                                 
  Leucopenia                                                                                                                                                                                                                                                            
  Positive               334            54                                            0.96 (0.60‐1.53)                                .865             147                                           47                                              0.90 (0.53‐1.52)   .684
  Negative               202            34                                                                                                             87                                            31                                                                 
  Anaemia                                                                                                                                                                                                                                                               
  Positive               291            45                                            0.85 (0.54‐1.33)                                .471             126                                           42                                              0.94 (0.56‐1.58)   .808
  Negative               245            43                                                                                                             108                                           36                                                                 
  Complement depressed                                                                                                                                                                                                                                                  
  Positive               377            59                                            0.86 (0.53‐1.39)                                .531             165                                           53                                              0.88 (0.51‐1.54)   .658
  Negative               159            29                                                                                                             69                                            25                                                                 
  Renal disorder                                                                                                                                                                                                                                                        
  Positive               284            38                                            0.68 (0.43‐1.07)                                .097             127                                           34                                              0.66 (0.39‐1.11)   .114
  Negative               252            50                                                                                                             107                                           44                                                                 
  Neurologic disorder                                                                                                                                                                                                                                                   
  Positive               121            23                                            1.24 (0.74‐2.09)                                .415             51                                            21                                              1.38 (0.76‐2.51)   .286
  Negative               415            65                                                                                                             183                                           57                                                                 
  Arthritis                                                                                                                                                                                                                                                             
  Positive               324            50                                            0.89 (0.56‐1.42)                                .627             141                                           46                                              1.02 (0.60‐1.73)   .952
  Negative               212            38                                                                                                             93                                            32                                                                 
  Anti‐dsDNA                                                                                                                                                                                                                                                            
  Positive               272            30                                            0.49 (0.31‐0.79)                                .003             125                                           26                                              0.42 (0.24‐0.72)   .002
  Negative               264            58                                                                                                             109                                           52                                                                 
  Anti‐RNP                                                                                                                                                                                                                                                              
  Positive               220            30                                            0.74 (0.46‐1.19)                                .210             98                                            27                                              0.73 (0.42‐1.24)   .242
  Negative               316            58                                                                                                             136                                           51                                                                 
  Anti‐Sm                                                                                                                                                                                                                                                               
  Positive               211            37                                            1.14 (0.72‐1.81)                                .576             91                                            33                                              1.20 (0.71‐2.02)   .504
  Negative               325            51                                                                                                             143                                           45                                                                 
  Anti‐SSA                                                                                                                                                                                                                                                              
  Positive               355            63                                            1.26 (0.77‐2.08)                                .359             153                                           56                                              1.31 (0.74‐2.30)   .355
  Negative               181            25                                                                                                             81                                            22                                                                 
  Anti‐SSB                                                                                                                                                                                                                                                              
  Positive               121            27                                            1.51 (0.92‐2.49)                                .103             50                                            24                                              1.64 (0.92‐2.92)   .095
  Negative               415            61                                                                                                             184                                           54                                                                 

Adjusted by age and gender.

95% CI, 95% confidence interval; AOR, adjusted OR value; A*P*, adjusted *P* value; n, number.

John Wiley & Sons, Ltd

4. DISCUSSION {#jcmm13672-sec-0008}
=============

The majority of studies have followed with interest on miRNA expression levels in diseases. Variations in the miRNA genes could contribute to abnormal secretion of miRNAs and even could be linked with susceptibility of diseases. A few studies have investigated the relationship between SNPs in miRNA regions and SLE. For example, Lofgren et al[5](#jcmm13672-bib-0005){ref-type="ref"} found that rs2431697 was not associated with expression levels of PTTG1, but with the miR‐146a, and the risk allele had lower expression of the miRNA. The above results indicated that SNP is potentially important in SLE aetiology. Changes in the miR‐17 expression have been observed in more human diseases, such as inflammatory and autoimmune diseases, viral infections and cancer.[10](#jcmm13672-bib-0010){ref-type="ref"}, [11](#jcmm13672-bib-0011){ref-type="ref"}, [12](#jcmm13672-bib-0012){ref-type="ref"} Carlsen et al[13](#jcmm13672-bib-0013){ref-type="ref"} demonstrated that miR‐17 expression was decreased significantly in plasma of SLE patients. Consistent with the result, we found that decreased level of miR‐17 in SLE patients was compared with healthy controls. This indicated that miR‐17 expression in plasma may suppress SLE development. One of the most characteristic antibodies of SLE is anti‐double‐stranded DNA (Anti‐dsDNA), which as a sensitive symbol in the disease. Overexpression of miRNA17‐92 cluster was associated high titres of anti‐DNA antibodies.[8](#jcmm13672-bib-0008){ref-type="ref"} We identified that rs9515692 was related to decreased risk of anti‐dsDNA. The finding further provides evidence that rs9515692 may be a protective factor for SLE. The molecular mechanism of how the rs9515692 leads to the up‐regulation of miR‐17 requires a more detailed analysis.

MiR‐17‐92 is strongly induced in activated T cells. Both mRNA and protein level of E2F1 were significantly decreased in SLE patients, miR‐17 of miR‐17‐92 cluster is critically involved in Th17 differentiation. Not only that, the miR‐17‐92 cluster also is an important mediator of Tfh cell biology. Deletion of the miR‐17‐92 cluster brought about decrease in numbers in Tfh and germinal centre of B cells, while transgenic expression of this miRNA cluster in CD4^+^ T cells caused increased numbers of both Tfh and germinal centre B cells.[14](#jcmm13672-bib-0014){ref-type="ref"}, [15](#jcmm13672-bib-0015){ref-type="ref"} Decreased expression of pro‐apoptotic molecule and phosphatase and tensin homologue on chromosome 10 in mice transgenic for the miR‐17‐92 cluster, lead to lymphoproliferation and other lupus manifestations.[16](#jcmm13672-bib-0016){ref-type="ref"} It is generally recognized that these cells play primary mediators in SLE. Given the key roles of miR‐17‐92 in SLE development, the positive results in our present study were biologically reasonable.

In conclusion, this is the first time reported *miR‐17‐92* gene polymorphisms associated with SLE susceptibility in an independent Chinese cohort. Analyses suggested that the rs9515692 decreased the risk of SLE in the Chinese population. Therefore, our findings may provide new insights into the development of SLE and create an opportunity to approach the diagnosis and treatment. In the future, further functional studies of rs9515692 will help us to define the potential biological mechanism of SLE.
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